Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | SAL-DaunoDouble trial: 90 mg vs 60 mg daunorubicin in 7+3 induction for AML

Christoph Röllig • 26 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Daunorubicin
SAL-DaunoDouble

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, outlines the results from the SAL-DaunoDouble trial comparing 90 mg versus 60 mg in a standard 7+3 induction regimen for newly diagnosed acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christoph Röllig

2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023
1:45
HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial
Christoph Röllig • 11 Dec 2023
2:26
Improving long-term outcomes with intensive chemotherapy in AML: looking to the future
Christoph Röllig • 11 Dec 2023
2:05
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig • 10 Dec 2022

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals